Latest available resultsQuarter ended June 30, 202610-Q · July 31, 2026
Filed with the SECModerna, Inc.
MRNAPharma & biotech
Next reportNovember 4, 2026pre-market · Analyst forecast -1.224 $/share
Revenue
$145.00M
▲ +2.1% vs prior year% YoY
Net income
−$782.00M
▲ +5.2% vs prior year% YoY
EPS
-1.97$
▲ +7.5% vs prior year% YoY
Net margin
-539.3%
▲ +41.7 percentage points vs prior year pp YoY
Revenue▲ +2.1 %
Margins (% of revenue)GrossOperatingNet
Net income▲ +5.2 %
EPS▲ +7.5 %
View financial tableQuarter ended June 30, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $145.00M | |
| Gross profit | $52.00M | 35.9 % |
| Operating income | −$815.00M | -562.1 % |
| Net income | −$782.00M | -539.3 % |
| R&D | $651.00M | 449.0 % |
| EPS (diluted) | -1.97 $ | |
| Balance sheet | ||
| Assets | $10.96B | |
| Liabilities | $4.20B | |
| Equity | $6.76B | |
| Cash | $1.72B | |
| Capital | ||
| Shares outstanding | 399.24M | as of 2026-07-24 |
| Public float | — | |